

Bennelong Australian Equities Fund

Performance update

As at 31 December 2019

Net client returns (after fees and expenses)

	1 mth	3 mths	1 Year	3 years pa	5 years pa	10 years pa	Since Inception** pa
Fund	-2.47%	4.12%	27.33%	15.37%	12.43%	10.88%	13.81%
Benchmark*	-2.02%	0.71%	23.77%	10.33%	9.07%	7.77%	10.76%
Value added	-0.45%	+3.41%	+3.56%	+5.04%	+3.36%	+3.11%	+3.04%

Performance figures are net of fees and expenses. 'Value added' calculation does not use rounded performance figures.

*S&P/ASX 300 Accumulation Index

**Inception date is 30 January 2009

Portfolio positioning

Sector	Fund Weight	Benchmark* Weight	Active Weight
Discretionary	25.3%	6.7%	18.6%
Health Care	21.6%	10.4%	11.3%
Materials	19.5%	18.2%	1.3%
Liquidity	0.8%	0.0%	0.8%
Consumer Staples	6.4%	5.7%	0.6%
IT	2.1%	2.7%	-0.6%
Communication	2.5%	3.6%	-1.1%
Industrials	6.9%	8.4%	-1.4%
Utilities	0.0%	1.8%	-1.8%
Energy	0.0%	5.4%	-5.4%
REIT's	1.7%	7.7%	-6.0%
Financials	13.2%	29.4%	-16.2%

Source: BAEP. *Benchmark is as for the Fund

Top Holdings

CSL
BHP Billiton
Aristocrat Leisure


Portfolio characteristics

	Fund	Benchmark*	
Return on Equity	19.4%	11.5%	Premium Quality
Debt/Equity	23.3%	42.3%	
Sales Growth	6.9%	2.5%	Superior Growth
EPS Growth	7.8%	4.6%	
Price/Earnings	21.3x	17.6x	Reasonable Valuation
Dividend Yield	2.6%	4.1%	
Beta	1.08	1	
Active Share	72%	na	Genuinely Active
No. of Stocks	29	296	

Source: BAEP. *Benchmark is as for the Fund.

Long-term performance

Growth of \$10,000 Since Inception



Source: BAEP

Bennelong Australian Equities Fund

Performance update
As at 31 December 2019

Performance

As you can see from the performance table on the front page, the fund performed well over the year and the December quarter.

The main contributor to the quarterly performance was the fund's outsized position in the healthcare sector, and in particular the positions in Fisher & Paykel Healthcare and CSL.

Fisher & Paykel Healthcare upgraded its earnings guidance in October on the release of a new mask in the treatment of obstructive sleep apnea. It then reported a strong half year result in November, with profit growth of 24%.

CSL continues to show strong momentum in its business. In December, the company held its R&D investor day, which showcased the R&D work going on behind the scenes to help build the pipeline of new applications and treatments. CSL is set to spend approximately US\$900 million (A\$1.3 billion) on R&D this financial year. Historically, CSL has run a very successful R&D program, and this spend has delivered high returns on investment and underpinned longer term growth in earnings.

The other main contributor to the fund's relative outperformance was the significant underweight stance to the underperforming banks. The banks currently face a number of regulatory, economic and other headwinds, and investors are starting to appreciate their weaker investment prospects. Their regulatory risks were highlighted again in the quarter with the announcement of Westpac facing significant fines over breaches of anti-money laundering laws.

As always, there were detractors, but they didn't detract much. The largest detractor was Afterpay, which gave back some of the outperformance delivered in previous periods.

Outlook

The December quarter continued what has been a strong run for the ASX in 2019. The many social, political and economic uncertainties that have overshadowed markets nevertheless remain.

It all goes to show that the market's moves and investor returns are unpredictable, at least in the short term. We'll still see quite well educated and precise guesses on what's in store for 2020. None, however, come with 2020 vision.

What we do know is the current state of things, and what this scenario presents in terms of the risk-reward equation. While it would be more interesting if it weren't, most of the time the stock-market acts quite rationally. This is how we see it today:

- Valuations: Equities trade more expensive on most valuation metrics compared to historical averages, but historical averages have never had to contend with rates of about 1%. To us, equity

valuations appear rational in their context. And on an earnings yield of approximately 6%, equities actually look attractively priced versus the competition (property, cash, bonds, etc).

- Fundamentals: These valuation metrics are underpinned by mostly healthy fundamentals. This includes *some* earnings growth, generally strong balance sheets and decent cash flows.
- Investor sentiment: Whilst difficult to generalise, investor sentiment remains mostly cautious. Stocks stand to benefit to the extent that investor confidence continues to gradually build, and investment dollars move from what is perceived as safe to what will deliver some return.

All up, it's likely the ASX produces reasonable returns over the medium term, albeit with ups and downs along the way. As always, there are pockets of risk and opportunity within the market, and that recommends towards a selective approach.

Portfolio positioning

True to our investment style, the fund is selectively invested in a group of high quality, growth stocks. These include names like CSL and Fisher & Paykel Healthcare that can be relied upon with some confidence to grow shareholder value over time.

Mostly, the portfolio is a selection of stocks determined by a 'bottom up' approach. Many of these stocks have risk-return dynamics that are driven by idiosyncratic factors, which itself provides a degree of diversification. That said, we must also take a 'top down' approach to assess risks on a portfolio-wide basis, including in relation to interest rates, trade negotiations and differing economic outcomes.

Some general themes across the portfolio include:

- A growth bias, but with a number of holdings acquired or trading on average or below-average PE multiples.
- A significant weighting to global companies and offshore earnings.
- Underweight the top 20 stocks, with a small exposure to the banks, and no exposure to other mature, slow growth oligopolies like Woolworths and Telstra.
- Underweight bond proxies such as utilities and telco's. We have an underweight position in the REITs, and otherwise have exposure to interest rates through long-duration growth stocks.
- Selective exposure to commodities, essentially through the major mining houses. We believe that demand can remain strong, especially with an uptick in Chinese and/or global growth.
- Very little exposure to domestic cyclicals, which we believe will continue to struggle with continuing weakness in the domestic economy.

Bennelong Australian Equities Fund

Performance update
As at 31 December 2019

About BAEP

Bennelong Australian Equity Partners (BAEP) is a boutique fund manager focused on Australian equities. It was founded in 2008 in partnership with Bennelong Funds Management. BAEP is a genuinely active fund manager with a consistent, disciplined and proven investment approach.

BAEP's investment philosophy is to selectively invest:

- in high quality companies;
- with strong growth outlooks; and
- underestimated earnings momentum and prospects.

BAEP's investment process is research-intensive with a focus on proprietary field research and is supported by macro-economic and quantitative insights.

About the Fund

The Bennelong Australian Equities Fund typically holds 25-60 stocks across the entire spectrum of the Australian share market. It primarily holds stocks from the S&P/ASX300 Index, although it can invest in stocks beyond this index.

Benefits of the Fund

- BAEP is an award winning and highly rated equities fund manager with an experienced and performance-orientated team.
- BAEP is a genuinely active and high conviction fund manager.
- The Fund is managed in accordance with BAEP's robust, disciplined and proven investment philosophy and process.
- The Fund has a track record of adding value by outperforming the market over the long term.

The Fund at a glance

Feature	Fund facts
APIR code	BFL0001AU
Benchmark	S&P/ASX 300 Accumulation Index
Investment objective	2% p.a. above benchmark measured over rolling 3-year periods
Investment manager	Bennelong Australian Equity Partners (BAEP)
Active stock limit	± 6%
Cash limit	0-10%
Inception date	30 January 2009
Recommended investment period	Medium to longer term (five years plus)
Buy/sell spread	+/-0.25%
Entry/exit fees	Nil
Management Fee	0.95% p.a. of Net Asset Value of the Fund

How to invest

The Fund is open to investors directly via the PDS, available on our website, or via a range of platforms.

Platforms

AMP: Elements Investment, Elements Pension, eWrap Investment Acc, eWrap Pension Acc, iAccess, Investment Service, Multifund, MyNorth, North, Pension Service, Portfolio Care, Portfolio Care eWrap, Summit, Super Service, Synergy, Wealthview eWrap Inv

ANZ (Grow, PortfolioOne) IOOF (AET, IPS, Lifetrack, Portfolio Services, SuperWrap, Pursuit Select, Employer Super, TPS)

AON Macquarie Wrap

BT (Wrap, Super Wrap, Panorama) Netwealth (Super Service, Wrap Service, IDPS)

CFS (FirstWrap, IX) Oasis (Voyage, Matrix)

Hub24 (Super, IDPS) One Answer (Frontier, OnePath)

Spitfire (Wealthtrac)

Contact details

For more information, call 1800 895 388 (AU) or 0800 442 304 (NZ) or visit baep.com.au.

The Fund is managed by Bennelong Australian Equity Partners, a Bennelong Funds Management boutique.

Disclaimer: This information is issued by Bennelong Funds Management Ltd (ABN 39 111 214 085, AFSL 296806) (BFML) in relation to the Bennelong Australian Equities Fund. The information provided is general information only. It does not constitute financial, tax or legal advice or an offer or solicitation to subscribe for units in any fund of which BFML is the Trustee or Responsible Entity (Bennelong Fund). This information has been prepared without taking account of your objectives, financial situation or needs. Before acting on the information or deciding whether to acquire or hold a product, you should consider the appropriateness of the information based on your own objectives, financial situation or needs or consult a professional adviser. You should also consider the relevant Information Memorandum (IM) and or Product Disclosure Statement (PDS) which is available on the BFML website, bennelongfunds.com, or by phoning 1800 895 388 (AU) or 0800 442 304 (NZ). BFML may receive management and or performance fees from the Bennelong Funds, details of which are also set out in the current IM and or PDS. BFML and the Bennelong Funds, their affiliates and associates accept no liability for any inaccurate, incomplete or omitted information of any kind or any losses caused by using this information. All investments carry risks. There can be no assurance that any Bennelong Fund will achieve its targeted rate of return and no guarantee against loss resulting from an investment in any Bennelong Fund. Past fund performance is not indicative of future performance. Information is current as at the date of this document. Bennelong Australian Equity Partners (ABN 69 131 665 122) is a Corporate Authorised Representative of Bennelong Funds Management Ltd (BFML), ABN 39 111 214 085, Australian Financial Services Licence No. 296806.